FDA Approves Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer November 26, 2024
FDA Study May Proceed Letter received for Pivotal Ph 3 Trial of Amezalpat Combination Therapy for the Treatment of 1L HCC November 19, 2024
Positive CHMP Opinion for Opdivo® (nivolumab) + Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with MSI-H or MRD Metastatic CRC November 19, 2024
UK MHRA approved toripalimab (LOQTORZI®)-chemo combos for the 1L treatment of metastatic NPC and unresectable advanced, recurrent, or metastatic ESCC November 19, 2024
FDA gives clearance to commence Ph 2 trial of leronlimab in patients with R/R MSS CRC November 13, 2024
Ph 1b Clinical Trial expanded to Evaluate TTX-080 in Combination with Cetuximab and Chemotherapy in Advanced Colorectal Cancer November 5, 2024
First Patient Enrolled in Ph 3 Trial of Ivonescimab Combination as 1L Therapy for Biliary Tract Tumors, Compared to Durvalumab November 5, 2024
Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented November 5, 2024
FDA clearance to commence Ph 2 trial of leronlimab in patients with R/R microsatellite stable CRC November 5, 2024
First Patient Dosed in Ph 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma October 29, 2024
Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented October 29, 2024
Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented October 29, 2024
VYLOY (zolbetuximab-clzb) Approved by US FDA for Treatment of Advanced Gastric and GEJ Cancer October 22, 2024
Positive CHMP Opinions for TEVIMBRA® as a 1L Treatment for Advanced/Metastatic Gastric or GEJ Cancer and Esophageal Squamous Cell Carcinoma October 22, 2024
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into 1L HCC Pivotal Trial October 15, 2024
Interim data from Ph 1 clinical study of misetionamide (GP-2250) in combination with gemcitabine in patients with pancreatic adenocarcinoma announced October 15, 2024
Key Progress and Upcoming Studies for Pelareorep Breast and Pancreatic Cancer Treatments Announced in Preparation for FDA Accelerated Approval Path October 8, 2024
Interim Ph 2 Data for GRANITE Neoantigen Targeting Immunotherapy in 1L Metastatic MSS CRC Announced October 8, 2024
FDA IND Clearance for ALE.P02, a Novel CLDN1-ADC for the Treatment of Squamous Cancers October 8, 2024
